Dihydromyricetin treats pulmonary hypertension by modulating CKLF1/CCR5 axis-induced pulmonary vascular cell pyroptosis.
Yan Q, Li P, Liu S, Sun Y, Chen C, Long J, Lin Y, Liang J, Wang H, Zhang L, Wang H, Wang H, Yang S, Lin M, Liu X, Yao J, Tian Z, Chen N, Yang Y, Ai Q.
Yan Q, et al. Among authors: sun y.
Biomed Pharmacother. 2024 Oct 25;180:117614. doi: 10.1016/j.biopha.2024.117614. Online ahead of print.
Biomed Pharmacother. 2024.
PMID: 39461017